In Vivo Pharmacodynamic Evaluation of NCI-N87 Line Based Gastric Cancer (CAT#: STEM-AE-0048-LGZ)

Introduction

The occurrence of gastric cancer is a multi-step and multi-factor progressive process. Under normal conditions, the proliferation and apoptosis of gastric mucosal epithelial cells maintain a dynamic balance. The maintenance of this balance depends on the joint regulation of oncogenes, oncosuppressor genes and some growth factors. In addition, cyclooxygenase-2 (COX-2) also plays an important role in the development of gastric cancer.
The oncogenes related to the development of gastric cancer include ras gene, bcl-2; The tumor suppressor genes included wild-type P53, APC, DCC, MCC, etc. Growth factors include epidermal growth factor (EGF), transforming growth factor-α (TGF-α), etc. Once this balance is disrupted, namely, oncogenes are activated, oncosuppressor genes are inhibited, growth factors are involved and DNA microsatellites are unstable, which causes excessive proliferation of gastric epithelial cells and fails to initiate apoptosis signals, and may gradually progress to gastric cancer. A variety of factors can affect the above regulatory system and participate in the occurrence of gastric cancer.

Add to Cart Please Inquire

Principle Applications Procedure Materials Notes Related Products

Principle

In vivo activity is the gold standard for the evaluation of drug biological activity, and it is the first verification of non-human comprehensive activity. In vivo pharmacodynamic evaluation plays a decisive role in the confirmation of candidate molecules and the screening of clinical target indications, and is an indispensable link in the development of new drugs. We provide a variety of disease animal models including inflammation, immunity, metabolism, etc., to meet the needs of different new drug research and development projects of customers, and accept customized services.
In vivo pharmacodynamic evaluation, as the basic research of new drugs, is carried out on animals. It is to verify the effect of drugs with the comprehensive participation of a number of other factors, and to understand the effect of drugs on a certain part of the body by comparing and analyzing the animal signs, in vitro organs, blood components, histone expression and tissue changes before and after drug administration.

Applications

Gastric Cancer

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder

Notes

Oncology efficacy Service package:
In vivo syngeneic model
In vivo CDX model
In vivo PBMC humanized model
In vivo transgenic mouse model
In vivo orthotropic or Metastasis tumor model

Other recommended products

In Vivo Pharmacodynamic Evaluation of HT1080 Cell Line Based Fibrosarcoma (CAT#: STEM-AE-0046-LGZ)
In Vivo Pharmacodynamic Evaluation of Bile Duct Ligation Induced Liver Fibrosis (CAT#: STEM-AE-0667-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hCD39 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0192-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hITGA5 Mice (Humanized Mice) (CAT#: STEM-AE-0618-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hRANKL Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0348-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hTNFA/hTNFR2/hTNFR1 Mice (Immune Checkpoint Humanized Mice) (CAT#: STEM-AE-0298-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hCD3E/hCD22 Mice (Humanized Mice) (CAT#: STEM-AE-0609-LGZ)
In Vivo Pharmacodynamic Evaluation of B-hANGPTL3 Mice (Cytokine Humanized Mice) (CAT#: STEM-AE-0461-LGZ)